Animal models for arthritis

Best Practice and Research: Clinical Rheumatology

Volumn 22, Issue 2, 2008, Pages 253-267

  Dinser, Robert ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

animal models; arthritis; future therapeutic targets; pathogenesis

Indexed keywords

ANGIOSTATIN; ANTIBIOTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CIPROFLOXACIN; COLLAGEN TYPE 9; CONNECTIVE TISSUE GROWTH FACTOR; CONNECTIVE TISSUE GROWTH FACTOR 2; CORTICOTROPIN; ENDOSTATIN; GLUCOSAMINE; GOLD; HEAT SHOCK PROTEIN 70; HLA B27 ANTIGEN; HYALURONIC ACID; IMATINIB; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; MATRIX PROTEIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BONE EROSION; BORRELIA INFECTION; CARTILAGE INJURY; CHONDROCALCINOSIS; CHRONIC MYELOID LEUKEMIA; CONNECTIVE TISSUE DISEASE; DISEASE MODEL; DRUG MECHANISM; FIBROBLAST; GOUT; HUMAN; JOINT DESTRUCTION; LYME DISEASE; NONHUMAN; OSTEOARTHRITIS; OSTEOCLAST; OSTEOPHYTE; PATHOGENESIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SPIROCHETE; SPONDYLOARTHROPATHY; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; GUINEA PIGS; MICE; OSTEOARTHRITIS; RABBITS; RATS; RHEUMATIC DISEASES; SALAMANDRIDAE;

EID: 42949131188     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2008.01.007     Document Type: Review

References (95)

1. Williams R.O., Feldmann M., and Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences of the United States of America 89 (1992) 9784-9788
2. Elliott M.J., Maini R.N., Feldmann M., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis & Rheumatism 36 (1993) 1681-1690
3. Joosten L.A., Helsen M.M., Saxne T., et al. Il-1ab blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. Journal of Immunology 163 (1999) 5049-5055
4. Bresnihan B., Alvaro-Gracia J.M., Cobby M., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis & Rheumatism 41 (1998) 2196-2204
5. Bathon J.M., Martin R.W., Fleischmann R.M., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. The New England Journal of Medicine 343 (2000) 1586-1593
6. Smolen J.S., Aletaha D., Koeller M., et al. New therapies for treatment of rheumatoid arthritis. Lancet 370 (2007) 1861-1874
7. Koenders M.I., Lubberts E., Oppers-Walgreen B., et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. American Journal of Pathology 167 (2005) 141-149
8. Maini R.N., Taylor P.C., Szechinski J., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis & Rheumatism 54 (2006) 2817-2829
9. Ruth J.H., Haas C.S., Park C.C., et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis & Rheumatism 54 (2006) 765-778
10. Brand D.D., Kang A.H., and Rosloniec E.F. Immunopathogenesis of collagen arthritis. Springer Seminars in Immunopathology 25 (2003) 3-18
11. Kannan K., Ortmann R.A., and Kimpel D. Animal models of rheumatoid and their relevance to human disease. Pathophysiology 12 (2005) 167-181
12. Sakaguchi S., and Sakaguchi N. Animal models of arthritis caused by systemic alteration of the immune system. Current Opinion In Immunology 17 (2005) 589-594
13. Vierboom M.P.M., Jonker M., Bontrop R.E., and t'Hart B. Modeling human arthritic diseases in non-human primates. Arthritis Research & Therapy 7 (2005) 145-154
14. Müller-Ladner U., Kriegsmann J., Franklin B.N., et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. American Journal of Pathology 149 (1996) 1607-1615
15. Tolbboom T.C., van der Helm-van Mil A.H., Nelissen R.G., et al. Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis. Arthritis & Rheumatism 52 (2005) 1999-2002
16. Fiehn C., Neumann E., Wunder A., et al. Methotrexate and albumin coupled with MTX supress synovial fibroblast invasion and cartilage degradation in vivo. Annals of the Rheumatic Diseases 63 (2004) 884-886
17. Neumann E., Judex M., Kullmann F., et al. Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway. Gene Therapy 9 (2002) 1508-1519
18. Schett G., Stolina M., Bolon B., et al. Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis & Rheumatism 52 (2005) 3192-3201
19. Hayer S., Redlich K., Korb A., et al. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. Arthritis & Rheumatism 56 (2007) 79-88
20. Wei S., Kitaura H., Zhou P., et al. IL-1 mediates TNF-induced osteoclastogenesis. The Journal of Clinical Investigation 115 (2005) 282-290
21. Stolina M., Adamu S., Ominsky M., et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. Journal of Bone and Mineral Research 20 (2005) 1757-1765
22. Kitaura H., Zhou P., Kim H.J., et al. M-CSF mediated TNF-induced inflammatory osteolysis. The Journal of Clinical Investigation 115 (2005) 3418-3427
23. Kamijo S., Nakajima A., Ikeda K., et al. Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochemical and Biophysical Research 347 (2006) 124-132
24. Schett G., Middleton S., Bolon B., et al. Additive bone protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis & Rheumatism 52 (2005) 1604-1611
25. Miyachi K., Ihara A., Hankins R.W., et al. Efficacy of imatinib mesylate (ST1571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukema. Clinical Rheumatology 22 (2003) 329-332
26. Dewar A.L., Cambareri A.C., Zannettino A.C., et al. Macrophage colony stimulating factor receptor, c-fms, is a novel target of imatinib. Blood 105 (2005) 3127-3132
27. Ando W., Hashimoto J., Nampei A., et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis. Journal of Bone and Mineral Research 24 (2006) 274-282
28. Paniagua R.T., Sharpe O., Ho P.P., et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. The Journal of Clinical Investigation 116 (2006) 2633-2644
29. Jarrett S.J., Conaghan P.G., Sloan V.S., et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis & Rheumatism 54 (2006) 1410-1414
30. Lu J., Kasama T., Kobayashi K., et al. Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. Journal of Immunology 164 (2000) 5922-5927
31. Mould A.W., Tonks I.D., Cahill M.M., et al. Vegfb gene knock-out mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis & Rheumatism 48 (2003) 2660-2669
32. Clavel G., Valvason C., Yamaoka K., et al. Relationship between angiogenesis and inflammation in experimental arthritis. European Cytokine Network 17 (2006) 202-210
33. Park Y.W., Kang Y.M., Butterfield J., et al. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. American Journal of Pathology 165 (2004) 2087-2098
34. Hashimoto A., Tarner I.H., Bohle R.M., et al. Analysis of vascular gene expression in arthritic synovium by laser-mediated microdissection. Arthritis & Rheumatism 56 (2007) 1094-1105
35. Afuwape A.O., Felödmann M., and Paleolog E.M. Adenoviral delivery of soluble VEGF receptor 1 abrogates disease activity in murine collagen-induced arthritis. Gene Therapy 10 (2003) 1950-1960
36. Yoo S.A., Bae D.G., Ryoo J.W., et al. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. Journal of Immunology 174 (2005) 5846-5855
37. Sone H., Kawakami Y., Sakauchi M., et al. Neutralisation of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochemical and Biophysical Research 281 (2001) 562-568
38. Tsai C.Y., Shiau A.L., Chen S.Y., et al. Amelioration of collagen-induced arthritis in rats by nanogold. Arthritis & Rheumatism 56 (2007) 544-554
39. Yin G., Liu W., An P., et al. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Molecular Therapy 5 (2002) 547-554
40. Kim J.M., Ho S.H., Park E.J., et al. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis & Rheumatism 46 (2002) 793-801
41. Jou I.M., Shiau A.L., Chen S.Y., et al. Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis. Arthritis & Rheumatism 52 (2005) 339-344
42. Davidson B.E.N., Vitters E.L., van der Kraan P.M., and van den Berg W.B. Expression of transforming growth factor-beta (TGFbeta) and the TGFbeta signalling molecule SMAD-2P in spontaneous and instability induced osteoarthritis: role in cartilage degradation, chondrogenesis and osteophyte formation. Annals of the Rheumatic Diseases 65 (2006) 1414-1421
43. Ameye L., and Young M.F. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy and corneal diseases. Glycobiology 12 (2002) 107-116
44. Ameye L., Aria D., Jepsen K., et al. Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB Journal 16 (2002) 673-680
45. Zemmyo M., Meharra E.J., Kuhn K., et al. Accelerated, aging-dependent development of osteoarthritis in alpha1 integrin-deficient mice. Arthritis & Rheumatism 48 (2003) 2873-2880
46. Hagg R., Hedbom E., Mollers U., et al. Absence of the alpha1(IX) chain leads to a functional knock-out of the entire collagen IX protein in mice. The Journal of Biological Chemistry 272 (1997) 20650-20654
47. Hu K., Xu L., Cao L., et al. Pathogenesis of osteoarthritis-like changes in the joints of mice deficient in type IX collagen. Arthritis & Rheumatism 54 (2006) 2891-2900
48. De Hooge A.S., van de Lo F.A., Bennink M.B., et al. Male IL-6 gene knock out mice developed more advanced osteoarthritis upon aging. Osteoarthritis and Cartilage 13 (2005) 66-73
49. Zhang Y.W., Su Y., Lanning N., et al. Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proceedings of the National Academy of Sciences of the United States of America 102 (2005) 11740-11745
50. Rountree R.B., Schor M., Chen H., et al. BMP receptor signalling is required for postnatal maintenance of articular cartilage. PLoS Biology 2 (2004) e355
51. Kamekura S., Hoshi K., Shimoaka T., et al. Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis and Cartilage 13 (2005) 632-641
52. Bolbos R., Benoit-Cattin H., Langlois J.B., et al. Knee cartilage thickness measurements using MRI: a 4 1/2 month longitudinal study in the meniscectomized guinea pig model of OA. Osteoarthritis and Cartilage 15 (2007) 656-665
53. Miot-Noirault E., Vidal A., Pastoureau P., et al. Early detection and monitoring of cartilage alteration in the experimental meniscectomised guinea pig model of osteoarthritis by 99mTc-NTP 15-5 scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging 34 (2007) 1280-1290
54. Kamekura S., Kawasaki Y., Hoshi H., et al. Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. Arthritis & Rheumatism 54 (2006) 2462-2470
55. Robertson C.M., Pennock A.T., Harwood F.L., et al. Characterizsation of pro-apoptotic and matrix-degenerative gene expression following induction of osteoarthritis in mature and aged rabbits. Osteoarthritis and Cartilage 14 (2006) 471-476
56. Appleton C.T.G., McErlain D.D., Pitelka V., et al. Forced mobilization accelerates pathogenesis: characterization of a preclinical surgical model of osteoarthritis. Arthritis Research & Therapy 9 (2007) R13
57. Bove S.E., Laemont K.D., Brooker R.M., et al. Surgically induced osteoarthritis in the rat results in the development of both osteoarthritis-like pain and secondary hyperalgesia. Osteoarthritis and Cartilage 14 (2006) 1041-1048
58. Reginster J.Y., Deroisy R., Rovati L.C., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised-controlled clinical trial. Lancet 357 (2001) 251-256
59. Tiraloche G., Girard C., Chouinard L., et al. Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis & Rheumatism 52 (2005) 1118-1128
60. Goldberg V.M., and Buckwalter J.A. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for a disease-modifying activity. Osteoarthritis and Cartilage 13 (2005) 216-224
61. Clemmons D.R., Busby W.H., Garmong A., et al. Inhibition of insulin-like growth factor binding protein 5 proteolysis in articular cartilage and joint fluid results in enhanced concentrations of insulin-like growth factor 1 and is associated with improved osteoarthritis. Arthritis & Rheumatism 46 (2002) 694-703
62. Inoue A., Takahashi K.A., Arai Y., et al. The therapeutic effects of basic fibroblast growth factor contained in gelatine hydrogel microspheres on experimental osteoarthritis in the rabbit knee. Arthritis & Rheumatism 54 (2006) 264-270
63. Van der Kraan P.M., Vitters E.L., van de Putte L.B.A., and van den Berg W.B. Development of osteoarthritic lesions in mice by metabolic and mechanical alterations in knee joints. American Journal of Pathology 135 (1989) 1001-1014
64. Guingamp C., Gegout-Pottie P., Philippe L., et al. Monoiodoacetate induced experimental osteoarthritis. Arthritis & Rheumatism 40 (1997) 1670-1679
65. Cledes G., Felizardo R., Foucart J.M., and Cerpentier P. Validation of a chemical osteoarthritis model in rabbit temporomandibular joint: a compliment to biomechanical models. International Journal of Oral and Maxillofacial Surgery 35 (2006) 1026-1033
66. Pomonis J.D., Boulet J.M., Gottshall S.L., et al. Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain 114 (2005) 339-346
67. Beyreuther B., Callizot N., and Stöhr T. Antinociceptive efficacy of lacosamide in the monosidum iodoacetate rat model for osteoarthritis pain. Arthritis Research & Therapy 9 (2007) R14
68. Scharstuhl A., Vitters E.L., van der Kraan P.M., and van den Berg W.B. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor ß/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis & Rheumatism 48 (2003) 3442-3451
69. Barve R.A., Minnerly J.C., Weiss D.J., et al. Transcriptional profiling and pathway analysis of monosodium iodoacetate-induced experimental osteoarthritis in rats: relevance to human disease. Osteoarthritis and Cartilage 15 (2007) 1190-1198
70. Nishida T., Kubota S., Kojima S., et al. Regeneration of defects in articular cartilage in rat knee joints by CCN 2. Journal of Bone and Mineral Research 19 (2004) 1308-1319
71. Grossin L., Cournil-Henrionnet C., Pinzano A., et al. Gene transfer with HSP70 in rat chondrocytes confers cytoprotection in vitro and during experimental osteoarthritis. FASEB Journal 20 (2006) 65-75
72. Gay S., Jones R.E., Huang G.Q., and Gay R.E. Immunohistologic demonstration of platelet-derived growth factor and sis-conogene expression in scleroderma. The Journal of Investigation Dermatology 92 (1989) 201-203
73. Yamakage A., Kikuchi K., Smith E.A., et al. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. The Journal of Experimental Medicine 175 (1992) 1227-1234
74. Distler J.H.W., Jüngel A., Huber L.C., et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis & Rheumatism 56 (2007) 311-322
75. Ghofrani H.A., Seeger W., and Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. The New England Journal of Medicine 353 (2005) 1412-1413
76. Hoi A.Y., Hickey M.J., Hall P., et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. Journal of Immunology 177 (2006) 5687-5696
77. Marquina R., Diez M.A., Lopez-Hoyos M., et al. Inhibition of B-cell death causes the development of an IgA nephropathy in (New Zealand White × C57BL/6)F1-bcl-2 transgenic mice. Journal of Immunology 172 (2004) 7177-7185
78. Gonzalez J., Tamayo E., Santiuste I., et al. CD4 + CD25 + T cell-dependent inhibition of autoimmunity in transgenic mice overexpressing human Bcl-2 in T-lymphocytes. Journal of Immunology 178 (2007) 2778-2786
79. Bachmann M.P., Bartsch H., Gross J.K., et al. Autoimmunity as a result of escape from RNA surveillance. Journal of Immunology 177 (2006) 1698-1707
80. Scofield R.H., Asfa S., Obeso D., et al. Immunization with short peptides from the 60-kDa Ro antigen recapitulates the serological and pathological findings as well as the salivary gland dysfunction of Sjögren's syndrome. Journal of Immunology 175 (2005) 8409-8414
81. Hacquard-Bouder C., Ittah M., and Breban M. Animal models of HLA-B27 associated diseases: new outcomes. Joint Bone Spine 73 (2006) 132-138
82. Hacquard-Bouder C., Falgarone G., Bosquet A., et al. Defective costimulatory function is a striking feature of antigen-presenting cells in an HLA-B27-transgenic rat model of spondyloarthropathy. Arthritis & Rheumatism 50 (2004) 1624-1635
83. Turner M.J., Sowders D.P., Delay M.L., et al. HLA-B27 misfolding in transgenic rats is associated with the activation of the unfolded protein response. Journal of Immunology 175 (2005) 2438-2448
84. Taurog J.D., Maika S.D., Satumtira N., et al. Inflammatory disease in HLA-B27 transgenic rats. Immunological Reviews 169 (1999) 209-223
85. Tran T.M., Dorris M.L., Satumtira N., et al. Additional human ß2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis & Rheumatism 54 (2006) 1317-1327
86. Bardos T., Zhang J., Mikecz K., et al. Mice lacking endogenous major histocompatibility complex class II develop arthritis resembling psoriatic arthritis at an advanced age. Arthritis & Rheumatism 46 (2002) 2465-2475
87. Cook P.W., Brown J.R., Cornell K.A., and Pittelkow M.R. Suprabasal expression of human amphiregulin in the epidermis of transgenic mice induces a severe, early-onset, psoriasis-like skin pathology: expression of amphiregulin in the basal epidermis is also associated with synovitis. Experimental Dermatology 13 (2004) 347-356
88. Zenz R., Eferl R., Kenner L., et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437 (2005) 369-375
89. Pendleton A., Johnson M.D., Hughes A., et al. Mutations in ANKH cause chondrocalcinosis. American Journal of Human Genetics 71 (2002) 933-940
90. Gurley K.A., Reimer R.J., and Kingsley D.M. Biochemical and genetic analysis of ANK in arthritis and bone disease. American Journal of Human Genetics 79 (2006) 1017-1029
91. Getting S.J., Lam C.W., Chen A.S., et al. Melanocortin 3 receptors control crystal-induced inflammation. FASEB Journal 20 (2006) 2234-2241
92. Getting S.J., Christian H.C., Flower R.J., and Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis & Rheumatism 46 (2002) 2765-2775
93. Steere A.C., and Glickstein L. Elucidation of Lyme arthritis. Nature Reviews. Immunology 4 (2004) 143-152
94. Ma Y., Seiler K.P., Eichwald E.J., et al. Distinct characteristics of resistance to Borrelia burgdorferi-induced arthritis in C57BL/6N mice. Infection and Immunity 66 (1998) 161-168
95. Steere A.C., and Angelis S.M. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis & Rheumatism 54 (2006) 3079-3086